Viatris Hikes Guidance With The Wind On Its Back At Halfway Stage

Low-End Guidance Jumps From $17.2bn To $17.5bn Total For 2021

 
• By Dean Rudge
  
Increased Sales
Several factors led Viatris to raise its guidance for 2021 • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business